Gene · 3598
IL13RA2: interleukin 13 receptor subunit alpha 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. IL13RA2: interleukin 13 receptor subunit alpha 2. Genes, record 3598. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3598
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q14627 | Interleukin-13 receptor subunit alpha-2 | 380 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents207
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| US 12636345 B2 | 2026-05-26 | 2 | Q14627 | Espacenet |
| EP 4705273 A2 | 2026-03-11 | 299 | Q14627 | Espacenet |
| EP 4705273 A2 | 2026-03-11 | 400 | Q14627 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 50171 | Q14627 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 50172 | Q14627 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 1083 | Q14627 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 761 | Q14627 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 16676 | Q14627 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2073 | Q14627 | Espacenet |
| EP 4606428 A2 | 2025-08-27 | 16 | Q14627 | Espacenet |
1 to 10 of 207
See all 207 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| CINTREDEKIN BESUDOTOX | CHEMBL2108583 | Interleukin-13 receptor subunit alpha-2 binding agent | BINDING AGENT |
Source ChEMBL
Trials9
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT00880061 | CINTREDEKIN BESUDOTOX | PHASE1 | ClinicalTrials.gov | |
| NCT00378235 | CINTREDEKIN BESUDOTOX | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT00089427 | CINTREDEKIN BESUDOTOX | PHASE1 | ClinicalTrials.gov | |
| NCT00076986 | CINTREDEKIN BESUDOTOX | PHASE3 | ClinicalTrials.gov | |
| NCT00053040 | CINTREDEKIN BESUDOTOX | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT00041587 | CINTREDEKIN BESUDOTOX | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT00036972 | CINTREDEKIN BESUDOTOX | PHASE1 | ClinicalTrials.gov | |
| NCT00024570 | CINTREDEKIN BESUDOTOX | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT00024557 | CINTREDEKIN BESUDOTOX | PHASE1 | ClinicalTrials.gov |
NIH grants1,705
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | IL13RA2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA033572 | Cancer Center Support Grant | 28 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 14 | 2025 |
| T32HL092332 | Training In Cell and Gene Therapy | 13 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 11 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 11 | 2025 |
| P30DK078392 | Digestive Health Center (DHC): Bench to Bedside Research in Pediatric Digestive Disease | 10 | 2025 |
| R35NS105068 | Preclinical development of breakthrough immunotherapy for brain tumors | 10 | 2025 |
| P30CA012197 | Cancer Center Support Grant | 9 | 2025 |
| P30CA060553 | The Robert H. Lurie Comprehensive Cancer Center | 8 | 2025 |
| P50CA221747 | SPORE for Translational Approaches to Brain Cancer | 8 | 2025 |
1 to 10 of 1,705Source NIH's project files
See all 1,705 nih grantsPapers2,877
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Chimeric Antigen Receptor T Cell Therapy for Glioblastoma: Clinical Advances and Emerging Strategies. | Hematol Oncol Clin North Am | 2026 | 42816201 | PubTator, text mining | PubMed |
| Peripheral Blood Immunogenomic Cytokine-receptor Signature (CXCR1, IL11RA, IL13RA2, CD19) Predicts HBV-related Cirrhosis: Public PBMC Transcriptome Mining and Nomogram Development. | Iran J Allergy Asthma Immunol | 2026 | 42801784 | PubTator, text mining | PubMed |
| Payload-Free Epitope Imprinted Polymer Nanoparticles Selectively Targeting IL-13Rα2 and Inhibition of Diffuse Midline Glioma Cells. | Cancers (Basel) | 2026 | 42794993 | PubTator, text mining | PubMed |
| BRD4 contributes to the cytokine-induced acquisition of an IL-13RA2-positive inflammatory fibroblast phenotype. | J Crohns Colitis | 2026 | 42635600 | PubTator, text mining | PubMed |
| Upadacitinib effectively suppresses IL13RA2 expression in primary human intestinal fibroblasts derived from Crohn's disease tissue. | Biochem Pharmacol | 2026 | 42603621 | PubTator, text mining | PubMed |
| Context-dependent promotion of epithelial-mesenchymal transition by IL-13Rα2/STAT6 signaling in colorectal cancer. | Mol Cell Biochem | 2026 | 42573974 | PubTator, text mining | PubMed |
| CAR T-cell therapy in pediatric brain tumors: a narrative review with comparative analysis of clinical trial eligibility criteria. | Front Oncol | 2026 | 42568366 | PubTator, text mining | PubMed |
| Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy. | Adv Sci (Weinh) | 2026 | 42554595 | PubTator, text mining | PubMed |
| Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics. | Clin Cancer Res | 2026 | 42550847 | PubTator, text mining | PubMed |
| EGFR inhibition promotes functional engraftment and graft survival via donor-derived CHI3L1 in fetal RPE suspension transplantation. | Cell Rep Med | 2026 | 42546699 | PubTator, text mining | PubMed |
1 to 10 of 2,877
See all 2,877 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3598
GET https://conductscience.org/api/genes/v1/3598/patents?page=2